Product
FT-002
1 clinical trial
1 indication
Indication
Retinitis PigmentosaClinical trial
An Open-label, Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intraocular Administration of FT-002 in Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa.Status: Recruiting, Estimated PCD: 2023-10-31